[1] Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. 2022 Aug;38(8)...
[4]James Chih-HsinYang et al. 1325P-Sunvozertinibas First-line Treatment in NSCLC Patients with EGFRExon20 Insertion Mutations.2023 ESMO. [5]Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer wi...
在《柳叶刀·呼吸医学》(The Lancet Respiratory Medicine,IF=76.2)发表题为“Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, ...
" EGFR Exon 20 Insertion Mutation in Japanese Lung Cancer, " Lung Cancer 58(3)324-328.Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kawano O, Yukiue H, Yokoyama T, Yano M and Fujii Y. EGFR exon 20 insertion ...
3.Yasuda H, Ichihara E, Sakakibara-Konishi J, et al. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021;162:140-146. doi:10.1016/j.lungcan.2021.10.006.
[5]Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin, 2022, 38(8): 1341-1350. doi: 10.1080/03007995.2022.2083326. ...
[1] Kwon CS, Lin HM, Crossland V, et al. Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. 2022 Aug;38(8):1341-1350. [2] Pan B, Liang J, Shi H, et al. Epidemiological charact...
EGFR 20 外显子插入(exon 20insertion, ex20ins)突变是一类 EGFR 突变的亚型,是 NSCLC 继 EGFR 19 外显子缺失(19-Del)和 21 外显子 L858R 点突变(21-L858R)两大常见突变外EGFR 的第三大突变。约占所有 NSCLC 的 1.8%～3%,约占 EGFR 突变型 NSCLC 的 4%～12%。
Cohort 5 is enrolling previously treated or treatment-naïve patients with EGFR or HER2 exon 20 insertion mutations, and cohort 6 is enrolling those with classical EGFR mutations who progressed on frontline osimertinib (Tagrisso) and developed an additional EGFR mutation. Cohort 7 is enrolling those...
The National Medical Products Administration of China has approved sunvozertinib for use in adult patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy....